The Supreme Court of India on Thursday, 8 October 2026, directed the Centre to constitute a committee to examine whether a statutory framework is needed to regulate pharmaceutical companies' marketing practices — including the offering of gifts, hospitality, travel facilities, and other benefits to doctors as prescription incentives. The direction came from a Bench of Justices Vikram Nath and Sandeep Mehta while hearing a petition demanding statutory checks on unethical interactions between drug firms and medical professionals.

What the Court Directed

Solicitor General Tushar Mehta informed the Bench that the Union government would constitute a three-member committee to assess whether a statutory regulatory framework is required for pharmaceutical companies' marketing conduct, and if so, recommend the form such regulation should take. The committee will solicit suggestions and objections from stakeholders before submitting its recommendations to the Centre.

The Centre has also been asked to file an affidavit confirming compliance with the court's directions. The matter is next scheduled for hearing on 29 January.

The Regulatory Asymmetry at the Heart of the Case

The petition drew attention to a structural imbalance in the existing framework: while doctors who accept gifts or hospitality from pharmaceutical companies face disciplinary consequences, there is no corresponding statutory mechanism to penalise or regulate the drug companies that offer such inducements in the first place. The Centre acknowledged before the court that the current framework does provide for action against doctors who accept such benefits, but conceded that direct statutory regulation of pharma companies on this issue remains unaddressed.

This is not the first time Indian courts or regulators have flagged the problem. Pharmaceutical industry self-regulation through the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) has existed for years but critics argue it lacks teeth, since compliance remains voluntary and enforcement has been inconsistent.

The Broader Medicine Pricing Context

The unethical marketing hearing is unfolding alongside a separate but related set of PILs before the same Bench examining medicine pricing, generic drugs, medical devices, and prescription practices. In those proceedings, the court has sharply questioned the wide gap between the price at which medicines are supplied to retailers and their Maximum Retail Price (MRP).

In a previous hearing, the court cited a cancer medicine carrying an MRP of ₹27,000 while being supplied to retailers at roughly ₹2,700 to ₹3,000 — a nearly ten-fold disparity. The court described the gap as 'broad daylight dacoity' and questioned why manufacturers should be permitted to fix MRPs substantially above the retailer supply price. It went further, noting that such extreme markups could undermine patient trust — a patient might suspect a medicine is spurious if a drug priced at ₹27,000 is suddenly available for ₹3,000.

The Bench also raised the question of whether a uniform margin could be prescribed for pharmaceutical products covered under the Essential Commodities Act, regardless of whether those medicines are classified as essential or non-essential under the Drug Price Control Order (DPCO).

Why This Matters for Patients and the Healthcare System

Unethical pharma marketing practices carry direct consequences for patients: when prescriptions are influenced by gifts or financial benefits rather than clinical evidence, patients may be steered toward costlier branded drugs over equally effective generics, inflating out-of-pocket healthcare expenditure. India's drug regulatory landscape has long been criticised for its fragmented oversight, with the Central Drugs Standard Control Organisation (CDSCO) focused on safety and quality while marketing conduct has fallen between regulatory jurisdictions.

A statutory framework — if the committee recommends one — could create enforceable penalties for pharma companies engaging in prohibited marketing, closing the asymmetry the petitioner flagged. Whether the committee's recommendations will carry legislative urgency, however, remains to be seen.

What Happens Next

The three-member committee's composition and terms of reference are yet to be notified. The Centre must file its compliance affidavit ahead of the next hearing on 29 January, at which point the court will assess progress. The companion PILs on medicine pricing are continuing on a parallel track before the same Bench, and further observations on MRP regulation are expected in upcoming sittings.